# HOOKIPA Pharma Inc. (HOOK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HOOK
## Company Profile
- Ticker: HOOK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 1.15 USD
- Market cap: Not available USD
- Last updated: 2026-06-02
## Business Overview
### Arenaviral Immunotherapy Platform
HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines.
### HB-700 for KRAS-Mutated Cancers
HB-700 is a multi-antigen therapy directed at common KRAS mutations across lung, colorectal, pancreatic, and other cancers. The program uses repeated administration of complementary vectors to sustain immune activity against tumor antigens.
### Clinical Proof from Eseba-Vec
The HB-700 strategy is supported by clinical experience with eseba-vec, formerly HB-200, in HPV16-positive head and neck cancer. That program demonstrated the platform's ability to induce antigen-specific immune responses in patients with advanced cancer.
### Partnered Infectious-Disease Programs
HOOKIPA has collaborated with Gilead on arenaviral immunotherapies for hepatitis B and HIV. Partner funding and milestone economics provide a second business model alongside internally led oncology development.
### Portfolio Prioritization
The company has paused or divested selected programs to focus capital on its highest-priority assets and collaborations. Its development model relies on specialized vector engineering, outsourced manufacturing, and external clinical networks.
## Why The Stock Is Moving

Current closing-price context is not available for HOOK.

## Future Catalysts

- Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.

## Recent News
- 2026-03-26 11:00 EST — [HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-oncology-assets-to-neotrail-thera-ff442692) — Source: HOOKIPA Pharma Inc.
- 2026-02-03 13:30 EST — [HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics-03f4fec9) — Source: HOOKIPA Pharma Inc.
- 2025-10-31 12:00 EST — [HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-hbv-and-hiv-assets-to-gilead-204a9211) — Source: HOOKIPA Pharma Inc.
- 2025-07-18 20:05 EST — [HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-comm-9406013c) — Source: HOOKIPA Pharma Inc.
- 2025-02-20 20:06 EST — [HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)](https://biopharmsignal.com/news/HOOK/hookipa-pharma-inc-hookipa-statement-regarding-potential-combination-for-poolbeg-5cecd13c) — Source: HOOKIPA Pharma Inc.